Eisai Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Eisai Co., Ltd.
Sixteen applications are in line for US FDA decisions in August. Ten are novel agents.
The expectation of a big second quarter sales decline proved true, but the situation is improving. Meanwhile, Merck & Co. is advancing two vaccines and an antiviral against the novel coronavirus.
UK-Rapid Test Consortium claims the CE marked, professional-use test is 99.4% accurate and plans to produce 500,000 tests a month from October and one million a month starting in 2021.
Better medtech industry-government dialog is needed to improve the adoption of innovative medical devices by the French health care system. The current pathway is not obvious or easy, according to local manufacturers.
- Other Names / Subsidiaries
- EA Pharma Co., Ltd.
- Eisai Laboratorios
- Eisai Mexico
- Eisai Participacoes Ltda. (Brazil Subsidiary)
- H3 Biomedicine
- HI-Eisai Pharmaceutical Inc.
- Liaoning TianYi Biological Pharmaceutical Co., Ltd.
- KAN Research Institute, Inc.
- MGI Pharma, Inc.
- Morphotek, Inc.
- Zycos Inc.